Norathyriol suppresses skin cancers induced by solar ultraviolet radiation by targeting ERK kinases

Cancer Research

Volumn 72, Issue 1, 2012, Pages 260-270

  Li, Jixia ^a   Malakhova, Margarita ^a   Mottamal, Madhusoodanan ^a   Reddy, Kanamata ^a   Kurinov, Igor ^c   Carper, Andria ^a   Langfald, Alyssa ^a   Oi, Naomi ^a   Kim, Myoung Ok ^a   Zhu, Feng ^a   Sosa, Carlos P ^a   Zhou, Keyuan ^b   Bode, Ann M ^a   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c Guangdong Medical College ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NORATHYRIOL; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER INHIBITION; CANCER PREVENTION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HYDROGEN BOND; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN CARCINOGENESIS; ULTRAVIOLET RADIATION;

ANIMALS; BLOTTING, WESTERN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; MICE; MODELS, MOLECULAR; NEOPLASMS, RADIATION-INDUCED; PROTEIN KINASE INHIBITORS; SKIN NEOPLASMS; SUNLIGHT; XANTHENES;

EID: 84855361776     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2596     Document Type: Article

References (44)

1. Bode AM, Dong Z. Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci STKE 2003;2003:RE2.
2. Jung SK, Lee KW, Byun S, Kang NJ, Lim SH, Heo YS, et al. Myricetin suppresses UVB-induced skin cancer by targeting Fyn. Cancer Res 2008;68:6021-9.
3. Nichols JA, Katiyar SK. Skin photoprotection by natural polyphenols: anti-inflammatory, antioxidant and DNA repair mechanisms. Arch Dermatol Res 2010;302:71-83.
4. Zheng D, Bode AM, Zhao Q, Cho YY, Zhu F, Ma WY, et al. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res 2008;68:3992-8.
5. Byun S, Lee KW, Jung SK, Lee EJ, Hwang MK, Lim SH, et al. Luteolin inhibits protein kinase C(epsilon) and c-Src activities and UVB-induced skin cancer. Cancer Res 2010;70:2415-23.
6. Assefa Z, Garmyn M, Bouillon R, Merlevede W, Vandenheede JR, Agostinis P. Differential stimulation of ERK and JNK activities by ultraviolet B irradiation and epidermal growth factor in human keratinocytes. J Invest Dermatol 1997;108:886-91. (Pubitemid 27272404)
7. She QB, Ma WY, Zhong S, Dong Z. Activation of JNK1, RSK2, and MSK1 is involved in serine 112 phosphorylation of Bad by ultraviolet B radiation. J Biol Chem 2002;277:24039-48. (Pubitemid 34951916)
8. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279-90. (Pubitemid 46763021)
9. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010;1802:396-405.
10. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995;9: 726-35.
11. Chieli E, Romiti N, Rodeiro I, Garrido G. In vitro effects of Mangifera indica and polyphenols derived on ABCB1/P-glycoprotein activity. Food Chem Toxicol 2009;47:2703-10.
12. Hsu MF, Lin CN, Lu MC, Wang JP. Inhibition of the arachidonic acid cascade by norathyriol via blockade of cyclooxygenase and lipoxygenase activity in neutrophils. Naunyn Schmiedebergs Arch Pharmacol 2004;369:507-15.
13. Lee HZ, Lin WC, Yeh FT, Lin CN, Wu CH. Decreased protein kinase C activation mediates inhibitory effect of norathyriol on serotonin-mediated endothelial permeability. Eur J Pharmacol 1998;353:303-13. (Pubitemid 28352278)
14. Wilkinson AS, Monteith GR, Shaw PN, Lin CN, Gidley MJ, Roberts- Thomson SJ. Effects of the mango components mangiferin and quercetin and the putative mangiferin metabolite norathyriol on the transactivation of peroxisome proliferator-activated receptor isoforms. J Agric Food Chem 2008;56:3037-42. (Pubitemid 351746026)
15. Teng CM, Ko FN, Wang JP, Lin CN, Wu TS, Chen CC, et al. Antihaemostatic and antithrombotic effect of some antiplatelet agents isolated from Chinese herbs. J Pharm Pharmacol 1991;43:667-9.
16. Ko FN, Lin CN, Liou SS, Huang TF, Teng CM. Vasorelaxation of rat thoracic aorta caused by norathyriol isolated from Gentianaceae. Eur J Pharmacol 1991;192:133-9.
17. Wang JP, Raung SL, Lin CN, Teng CM. Inhibitory effect of norathyriol, a xanthone from Tripterospermum lanceolatum, on cutaneous plasma extravasation. Eur J Pharmacol 1994;251:35-42.
18. Kang JJ, Cheng YW, Ko FN, Kuo ML, Lin CN, Teng CM. Induction of calcium release from sarcoplasmic reticulum of skeletal muscle by xanthone and norathyriol. Br J Pharmacol 1996;118:1736-42. (Pubitemid 26252669)
19. Hsu MF, Raung SL, Tsao LT, Lin CN, Wang JP. Examination of the inhibitory effect of norathyriol in formylmethionyl-leucyl-phenylalanine- induced respiratory burst in rat neutrophils. Free Radic Biol Med 1997;23:1035-45.
20. Wang JP, Raung SL, Tsao LT, Lin CN. Evidence for the involvement of protein kinase C inhibition by norathyriol in the reduction of phorbol ester-induced neutrophil superoxide anion generation and aggregation. Eur J Pharmacol 1997;336:81-8.
21. Lin CN, Liou SS, Ko FN, Teng CM. Gamma-pyrone compounds. II: Synthesis and antiplatelet effects of tetraoxygenated xanthones. J Pharm Sci 1992;81:1109-12.
22. Otwinowski Z, Minor W. Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol 1997;276:307-326. (Pubitemid 27085611)
23. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 2002;58:1948-54. (Pubitemid 35337293)
24. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004;60:2126-32. (Pubitemid 41742764)
25. Laskowski RA, MacArthurMW,Moss DS, Thornton JM. PROCHECK:a program to check the stereochemical quality of protein structures. J Appl Cryst 1993;26:283-91.
26. Ohori M, Kinoshita T, Okubo M, Sato K, Yamazaki A, Arakawa H, et al. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem Biophys Res Commun 2005;336:357-63. (Pubitemid 41253441)
27. Russo AE, Torrisi E, Bevelacqua Y, Perrotta R, Libra M, McCubrey JA, et al. Melanoma: molecular pathogenesis and emerging target therapies (Review). Int J Oncol 2009;34:1481-9.
28. Bode HB, Zeeck A. UV mutagenesis and enzyme inhibitors as tools to elucidate the late biosynthesis of the spirobisnaphthalenes. Phytochemistry 2000;55:311-6.
29. Aronov AM, Baker C, Bemis GW, Cao J, Chen G, Ford PJ, et al. Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors. J Med Chem 2007;50:1280-7. (Pubitemid 46496327)
30. Meloche S, Seuwen K, Pages G, Pouyssegur J. Biphasic and synergistic activation of p44mapk (ERK1) by growth factors: correlation between late phase activation and mitogenicity. Mol Endocrinol 1992;6:845-54.
31. Pages G, Lenormand P, L'Allemain G, Chambard JC, Meloche S, Pouyssegur J. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci U S A 1993;90:8319-23. (Pubitemid 23277659)
32. 2-arrest to prevent mitotic entry with damaged DNA. Cell Cycle 2007;6:1147-52.
33. Bock C, Waldmann KH, Ternes W. Mangiferin and hesperidin metabolites are absorbed from the gastrointestinal tract of pigs after oral ingestion of a Cyclopia genistoides (honeybush tea) extract. Nutr Res 2008;28:879-91.
34. Wang H, Ye G, Ma CH, Tang YH, Fan MS, Li ZX, et al. Identification and determination of four metabolites of mangiferin in rat urine. J Pharm Biomed Anal 2007;45:793-8. (Pubitemid 350087555)
35. Singh RP, Agarwal R. Natural flavonoids targeting deregulated cell cycle progression in cancer cells. Curr Drug Targets 2006;7:345-54. (Pubitemid 43744850)
36. 2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 2006;25:1053-69.
37. Tamemoto H, Kadowaki T, Tobe K, Ueki K, Izumi T, Chatani Y, et al. Biphasic activation of two mitogen-activated protein kinases during the cell cycle in mammalian cells. J Biol Chem 1992;267:20293-7.
38. 2/M progression. J Cell Biol 2009;185:409-22.
39. 2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells. Arch Biochem Biophys 2009;490:70-5.
40. 2/M-phase cell cycle arrest and p53 expression. Phytother Res 2010;24:1870-6.
41. Cooper SJ, Bowden GT. Ultraviolet B regulation of transcription factor families: roles of nuclear factor-kappa B (NF-kappaB) and activator protein-1 (AP-1) in UVB-induced skin carcinogenesis. Curr Cancer Drug Targets 2007;7:325-34. (Pubitemid 46849237)
42. Kinoshita T, Warizaya M, Ohori M, Sato K, Neya M, Fujii T. Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative. Bioorg Med Chem Lett 2006;16:55-8. (Pubitemid 41625640)
43. Wang Z, Canagarajah BJ, Boehm JC, Kassisa S, Cobb MH, Young PR, et al. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998;6:1117-28. (Pubitemid 28434115)
44. Rastelli G, Rosenfeld R, Reid R, Santi DV. Molecular modeling and crystal structure of ERK2-hypothemycin complexes. J Struct Biol 2008;164:18-23.